Screening Social Determinants of Health in CKM Food insecurity, housing instability and financial strain as core clinical variables
Keywords:
Cardiovascular–kidney–metabolic syndrome, Social determinants of health, Food insecurity, Housing instability, Financial strain, Intimate partner violence, Multidisciplinary care\, Medication adherence, Population health, American Heart Association guidelineAbstract
AbstractThe 2026 cardiovascular–kidney–metabolic (CKM) guideline reframes social context as a core clinical pillar rather than background “risk,” elevating routine screening of social determinants of health (SDOH) to the same encounter as estimated glomerular filtration rate and urine albumin-to-creatinine ratio assessment. The document highlights food insecurity, housing instability and financial strain as priority SDOH, each independently associated with incident CKM syndrome, accelerated progression and adverse outcomes once disease is established. In addition, intimate partner violence is explicitly named, and the guideline calls for systematic engagement of social workers, community health workers and other allied professionals as integral members of CKM care teams.
Biological and epidemiologic rationale is grounded in the recognition that obesity and related metabolic disturbances arise from intertwined social, behavioural and biological drivers, in a context where overweight and obesity affect most of the U.S. adult population. Within this paradigm, identifying patients who cannot reliably access food, housing or medications is described as practice-changing information that should reshape treatment planning as directly as any laboratory value, shifting emphasis from prescriptions alone to activation of social and community-based referral pathways.
The newsletter summarised here argues that documenting food insecurity, housing instability and financial strain functions as a measurable clinical variable that predicts medication access, visit adherence and capacity for sustained lifestyle change, thereby informing prognostic assessment as robustly as many traditional biomarkers. Integration of pharmacists and other allied professionals extends the impact of SDOH screening through medication affordability counselling, adherence support and triage to appropriate services, particularly in resource-constrained settings. Routine SDOH documentation at the point of CKM care is therefore positioned as both a clinical imperative and an administrative tool for equitable population-health planning and allocation of limited specialty resources.
![NEWSLETTER 7 Screening Social Determinants of Health in CKM Food insecurity, housing instability and financial strain as core clinical variables Figure 7. Screening Social Determinants of Health in CKM — mechanism overview (illustrative; labels added for education). The 2026 guideline elevates social context from background factor to core clinical pillar. It recommends routine assessment of social determinants of health (SDOH) closely linked with CKM development and complications, and treats addressing adverse SDOH as a key component of holistic CKM care.1 This is a notable expansion of scope for a cardiometabolic guideline. The document is specific about what to screen for: food insecurity, housing instability, and financial strain, each of which independently raises the risk of developing CKM syndrome and of poor outcomes once it is established.2,3 Named social risk factors also include intimate partner violence, and the guideline explicitly calls for engaging social workers and community health workers as part of the care team.4 The rationale is grounded in the biology of the syndrome itself. Ndumele notes that obesity develops from “a complex array of social, behavioral and biological factors,” and that addressing social risks, while “a very big challenge... [is] not one that I think we can afford to ignore.”4 With obesity and overweight affecting more than 70% of the U.S. population, the guideline frames CKM as a systemic challenge that cannot be solved by pharmacology alone.4 For clinicians, the practical implication is that a brief, validated SDOH screen belongs in the same encounter as the eGFR and UACR. Identifying a patient who cannot afford medication or reliably access food changes the treatment plan as much as any lab value—and points toward referral pathways rather than prescriptions alone. Framing social risk as a clinical variable also has measurable downstream value. Food insecurity, housing instability, and financial strain each shape whether a patient can afford medication, attend follow-up, or maintain dietary change—so documenting them predicts adherence as reliably as many laboratory markers.2 The guideline’s inclusion of intimate partner violence and its call to embed social workers and community health workers acknowledge that CKM outcomes are shaped well outside the clinic, and that pharmacology alone cannot close the gap.4 Multidisciplinary teams extend this reach. Pharmacists and allied professionals have a defined role in addressing SDOH and bridging gaps across CKM care, from medication affordability counselling to adherence support.5 In resource-constrained settings, systematically documenting social risk also supports population-health planning and equitable allocation of scarce specialist resources—making SDOH screening both a clinical and an administrative priority. References 1. 2026 CKM Guideline — Top Things to Know, professional.heart.org, June 9, 2026. https://professional.heart.org/en/science-news/2026-guideline-for-the-prevention-detection-evaluation-and-management-of-ckm-syndrome/top-things-to-know 2. First-ever guideline on CKM syndrome issued, AHA Newsroom, June 9, 2026. https://newsroom.heart.org/news/first-ever-guideline-on-cardiovascular-kidney-metabolic-syndrome-issued 3. First-Ever Guideline Addresses CKM Syndrome, ACC.org Journal Scan, June 9, 2026. https://www.acc.org/latest-in-cardiology/journal-scans/2026/06/08/17/44/first-ever-guideline-addresses-ckm-syndrome 4. A new guideline links care for heart, kidney and metabolic diseases, Science News, June 10, 2026. https://www.sciencenews.org/article/heart-diabetes-kidney-disease-treatment 5. Review of GLP-1 and Dual GLP-1/GIP receptor agonists, Am J Health Syst Pharm, June 2025 (PMID 40197714). https://pubmed.ncbi.nlm.nih.gov/40197714/ 6. New guideline reframes weight as health risk, AHA Newsroom, June 9, 2026. https://newsroom.heart.org/news/new-guideline-reframes-weight-as-health-risk-tied-to-diabetes-kidney-and-heart-conditions](https://thediabzen.com/public/journals/1/article_47_cover_en.jpg)
